IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

AI-Driven Tools for Regulatory Document Development: Modernizing eCTD, NDA, and ANDA Submissions

[1]Gautam B. Nariya, [2]Dr. Hitesh G. Raval, [3]Karan M. Patel

[1]M. Pharm Research Scholar, [2] Professor, [3]Project Manager

[1,2]Department of Regulatory Affairs, Anand Pharmacy College, Anand, Gujarat, India

[3]Baroque Pharmaceutical Pvt Ltd, Anand, Gujarat, India

Abstract

The preparation and submission of regulatory dossiers such as the electronic Common Technical Document (eCTD), New Drug Applications (NDA), and Abbreviated New Drug Applications (ANDA) remain highly complex, time intensive, and vulnerable to human error. Global regulatory authorities, including the US FDA, EMA, and CDSCO, enforce stringent and region-specific submission standards, resulting in significant operational burden and approval delays. This review examines the transformative role of Artificial Intelligence (AI) and Machine Learning (ML) in modernizing regulatory document development across the full submission lifecycle. Particular emphasis is placed on AI-enabled content authoring, automated dossier assembly, semantic consistency checks, predictive compliance analytics, and lifecycle management for both NDA and high-volume ANDA submissions. The integration of AI technologies enhances data consistency, reduces technical deficiencies, and supports real-time regulatory compliance, positioning AI-driven platforms as critical enablers for efficient, transparent, and future-ready regulatory submissions in the era of eCTD v4.0.

Keywords

Artificial Intelligence, eCTD, NDA, ANDA, Regulatory Affairs, Generative AI, Compliance, Document Automation

1. INTRODUCTION

The pharmaceutical sector experiences ongoing demands to hasten drug development schedules while maintaining rigorous compliance with international regulatory requirements. Regulatory submissions—the essential last step in introducing a drug to the market—require assembling extensive data (often surpassing 100,000 pages for a standard NDA) into uniform electronic formats such as the eCTD. [1-4]

1.1 The Regulatory Documentation Challenge

The preparation of regulatory documents faces numerous significant challenges that require advancements in digital technology:

- Growing Complexity: Regular revisions to protocols (e.g., ICH Q-series, regional Module 1 specifications) and the massive amount of accompanying information.[5]
- Human Error Risk: Manual activities such as hyperlinking, bookmarking, version management, and formatting checks can cause inconsistencies that may lead to failures in technical validation and rejections from regulatory bodies.[6]
- Duration and Expenses: The resource-demanding aspects of publishing and validating dossiers result in prolonged periods and substantial operational expenses.[7]

1.2 The Evolution to AI-Powered Submissions

The regulatory process has moved from paper submissions to the digitized, internationally recognized eCTD format.[8] The upcoming evolutionary stage involves the integration of AI, shifting the process from mere structural digitalization to smart automation.[9] AI tools utilize machine learning (ML), natural language processing (NLP), and generative models to integrate intelligence into document generation and compliance processes.[10][11]

2. AI MECHANISM AND APPLICATIONS IN REGULATORY DOCUMENT PREPARATION

AI systems currently assist throughout the complete regulatory document lifecycle, from initial content creation to final submission validation and updates after approval. Their fundamental approach utilizes sophisticated machine-learning and natural-language-processing algorithms to examine both unstructured text (e.g., clinical trial reports, CMC documentation) and structured data (e.g., regulatory metadata, clinical databases). Transforming this information into significant patterns allows AI to execute intricate, knowledge-heavy tasks such as document categorization, consistency verification, data extraction, and automatic content creation. [12][13]



Figure 1. AI-Driven Workflow in Regulatory Document Preparation and Submission

2.1 Classification of AI-Driven Regulatory Tools

AI-driven regulatory systems can be broadly categorized based on their functional role in regulatory document development:

2.1.1 AI-Assisted Authoring and Content Generation Tools [12],[16]

These tools employ generative AI and NLP models to draft and refine regulatory documents.

- Automated generation of Module 2 summaries (QOS, Clinical Overview, Nonclinical Overview)
- Terminology harmonization and tone standardization
- Drafting responses to regulatory queries (RTQs)

2.1.2 AI-Based Dossier Assembly and Publishing Tools [20]

Focused on transforming authored documents into submission-ready eCTD sequences.

- Automated document classification into CTD modules
- Intelligent hyperlinking and bookmarking
- Regional format validation and technical compliance checks

2.1.3 AI-Enabled Quality and Compliance Intelligence Tools [23]

These systems act as advanced quality checkpoints prior to submission.

- Cross-module semantic consistency verification
- Detection of missing, conflicting, or outdated information
- Predictive analytics for potential regulatory deficiencies

2.1.4 AI-Integrated Lifecycle and Change Management Tools [22]

Designed to support post-approval maintenance and global lifecycle activities.

- Version control across NDA and ANDA supplements
- Automated impact analysis for variations and amendments
- Synchronization of regional submissions and approvals

2.2 Content Creation and Development: Screening to Intervention

Generative AI (GenAI) is revolutionizing the function of medical writers by streamlining the creation of standard or data-driven materials, enabling human specialists to concentrate on scientific strategy.[14]

- Creating Summaries: GenAI models can examine unprocessed information from clinical trial reports (CSRs), non-clinical research, and CMC sections to produce initial drafts of Module 2 summaries (e.g., Clinical Overview, Quality Overall Summary) or documents intended for patients, greatly minimizing the time spent on authorship.[15][16]
- Consistency and Tone: NLP systems guarantee uniformity in terminology, uphold the necessary regulatory tone, and synchronize cross-references (e.g., between Module 3 and Module 5 summaries).[17]
- Response-to-Queries (RTQs): AI-driven solutions analyse internal data stores, past RTQs, and regulatory communications to automatically generate accurate replies to agency inquiries, speeding up the review process.[18]

2.3 Dossier Assembly and Publishing

The publishing phase, which transforms written documents into the final, compliant eCTD format, greatly benefits from automation

Table 1. AI-Powered Automation in Document Processing: Features and Advantages

Feature	AI Mechanism	Visible Benefits (Symptoms)
Document Classification	ML/NLP	Automatically sorting documents into their appropriate eCTD modules (e.g., Module 3.2.S, 5.3.5) and attaching metadata (Study ID, document type)[10]
Hyperlinking & Bookmarking	NLP/Semantic Web	Automated identification of references within documents and the creation of contextually relevant hyperlinks and bookmarks, minimizing human error[19][20][22]
Format Validation	Machine Learning	Reviewing for formatting errors (font, margin, page size) and adherence to local guidelines, confirming readiness for submission[19]
Real-time Compliance	Guideline Integration Engines	Monitoring updates in international standards and promptly identifying non-compliant material, improving audit preparedness[21][10]

2.4 **Quality and Compliance:**

The main motive for adopting AI is to reduce the significant risk of human mistakes present in manual regulatory procedures. AI functions as a smart quality checkpoint prior to submission.[10]

- Semantic Consistency: AI tools execute thorough semantic evaluations, surpassing basic validation guidelines. For example, they can highlight discrepancies where a drug formulation referenced in the Module 3 Quality section does not align with the one outlined in the Module 5 Clinical summary.[23][24]
- Predictive Analytics: By utilizing historical submission data and regulatory responses for training, AI models can estimate the chances of receiving a particular query or deficiency letter from a regulatory body, enabling the sponsor to proactively tackle possible problems.[25][26]

- Lifecycle Management (ACTD/NDA/ANDA): For abbreviated submissions (ANDA) and subsequent modifications, AI assists in overseeing version control, guaranteeing that all regional documents show the most recent approved modifications and enabling quicker responses to regulatory inquiries.[27][10]

3 THE ROLE OF AI IN THE eCTD V4.0 TRANSITION

The transition to eCTD v4.0 is a global initiative that fundamentally changes the submission paradigm from a document-centric to a data-centric model, using HL7 Regulated Product Submission (RPS) standards. This transition necessitates advanced AI and automation tools. [28][29]

3.1 eCTD v4.0 and Data Structure

eCTD v4.0 implements two-way communication and depends significantly on structured metadata and detailed document elements.

- Metadata Automation: AI plays a crucial role in precisely tagging and organizing documents according to the updated, comprehensive metadata standards of v4.0. Machine learning can assess document content and context to automatically assign intricate attributes, which is unfeasible to do by hand. [32]
- Integration with RIMS: Advanced AI platforms are crafted to effortlessly integrate with Regulatory Information Management Systems (RIMS) and cloud-based dossier management systems, consolidating content and intelligence for worldwide collaboration. [33]

3.3 Regulatory Agency Adoption Stages (FDA/EMA/Global)

Regulatory bodies are progressing through the adoption phases for eCTD v4.0:

- FDA: CDER and CBER are now accepting eCTD v4.0 submissions on an optional basis, with upcoming phases focusing on forward compatibility for current v3.2.2 applications and bidirectional communication.[34][35][36]
- EMA: The European Medicines Agency is testing eCTD v4.0 for Centrally Authorised Products (CAPs), with compulsory implementation anticipated in the next few years (schedule may change, but probably around 2026-2028 worldwide). The phased rollout highlights the necessity for flexible AI solutions capable of supporting both v3.2.2 and v4.0 at the same time.[37][38][39]

4 CHALLENGES AND FUTURE OUTLOOK

Although the advantages are evident, integrating AI into the creation of regulatory documents encounters various significant obstacles:

- Data Quality and Verification: AI tools need to be verified according to GxP standards (e.g., 21 CFR Part 11) to guarantee the trustworthiness and consistency of their results. Skewed or low-quality training data may result in imprecise document creation or mistaken compliance alerts.[40][41][42]
- Regulatory Acceptance and Trust: Authorities stress the importance of having "human-in-the-loop" oversight. Businesses are required to offer transparent audit trails and guarantee the understandability of content and decisions produced by AI.[43][44]
- Expense of Implementation: Integrating AI platforms with current document management systems (DMS) and RIMS necessitates substantial initial investment in technological infrastructure and tailored training.[45][46]

The future of regulatory document preparation indicates complete automation of dossier creation, instant compliance oversight, and the implementation of AI chatbots/assistants to aid regulatory teams in quick query resolution. Through the adoption of AI, companies can gain a competitive advantage, facilitate quicker market entry and reduce compliance risks.[47][48]

4.1 Limitations and Compliance Risks

- The 'Black Box' Challenge: Numerous sophisticated ML and deep learning systems function as "black boxes," complicating efforts to track their logic or the origin of data behind a produced statement. In a regulatory environment where traceability and auditability are crucial (ICH Q10 standards), absence of interpretability presents a major risk.[49]
- Data Bias and Mistakes: AI systems perform at the level of the data used for their training. When historical submissions utilized as training data include inherent human or terminology biases, the AI could sustain and intensify these mistakes, possibly resulting in inaccurate interpretations of safety information or violations of compliance.[50]
- Data Protection and Privacy: Utilizing cloud-based or third-party AI systems to handle sensitive information (clinical study reports, proprietary CMC information) presents major data security and intellectual property issues, necessitating thorough platform validation.[51]

4.3 Human Oversight in Regulatory Compliance

AI serves as an enhancement tool rather than a substitute for human regulatory knowledge. The future function of the Regulatory Affairs expert will transition from document creator to AI overseer and strategic planner.[52]

- Validation and Interpretation: Experts will need to verify the AI-generated material and understand the system's semantic results, especially when the AI identifies possible compliance concerns. This guarantees that the final accountability for the accuracy of the submission lies with the sponsor.[53][54]
- Strategic Design: Regulatory experts will progressively concentrate on architecting the AI's data model, selecting high-quality training datasets, and establishing intricate cross-validation protocols that power the automation framework, shifting from tactical document oversight to strategic technological empowerment.[52][55]

5 AI-DRIVEN REGULATORY OPERATIONS IN PHARMA: CASE STUDIES AND TRENDS

5.1 Veeva Vault RIM

The platform has become a reliable standard in the biopharmaceutical industry, extensively utilized by Pfizer, GSK, Takeda, Moderna, and Novartis.

Its built-in AI features enhance dossier creation by automating metadata tagging, classifying documents, and managing versions. These characteristics assist regulatory teams in guaranteeing that every document is correctly indexed and matched with the relevant module of the eCTD. The system additionally facilitates submission planning by offering predictive insights into regulatory timelines drawn from historical data. Veeva Vault RIM, through its cloud-based setup and smart workflow routing, greatly minimizes manual documentation mistakes and speeds up the process of global submissions. [56]

5.3 IQVIA SmartSolve / Regulatory Technology Suite

It is widely used by Johnson & Johnson, Eli Lilly, Sanofi, and AstraZeneca, the solution has become a trusted choice across the pharmaceutical industry.

IQVIA provides a sophisticated range of AI-driven regulatory tools, with SmartSolve standing out as a key solution for managing quality and compliance. Its NLP algorithms can assess clinical, nonclinical and CMC documents to identify important regulatory-related information and highlight discrepancies. IQVIA's AI conducts automated gap analyses, detecting absent data or noncompliant elements prior to dossier compilation. This minimizes delays in late-stage submissions and improves overall document quality. [57]

5.4 Parexel AI-Enabled Regulatory Solutions

It is widely used by mid-size and large pharmaceutical companies partnering with Parexel; the platform is recognized for its consistency and impact.

Parexel, a leading CRO, offers AI-powered regulatory solutions frequently utilized by pharmaceutical firms looking for external assistance with eCTD preparation and submission oversight. Their machine-learning systems aid in automating dossier organization, verifying content, and performing smart quality assessments on clinical, CMC, and safety documents. Parexel's AI can synchronize submission materials for different regions, allowing firms to effectively create simultaneous submissions for international markets. The system further automates the publishing and validation procedures, lowering the chances of technical rejections by organizations like the FDA or EMA.

5.5 Freyr SUBMIT PRO & Freyr RIMS

Freyr's AI-driven regulatory platforms, such as SUBMIT PRO and Freyr RIMS, are extensively utilized by generic and developing pharmaceutical firms for eCTD submission and lifecycle management. These tools offer automated verification against regional eCTD standards, confirming that submissions comply with FDA, EMA, Health Canada, MHRA, and GCC formatting guidelines. AI-powered compliance assessment and error detection assist in pinpointing possible technical problems prior to submission, minimizing the likelihood of refusals-to-file (RTFs) or letters of technical rejection. Freyr's platforms also facilitate automated sequence creation and comprehensive dossier transformation, rendering them especially efficient for firms handling numerous regional submissions, including ANDAs and international CTD variations. [59]

5.6 ArisGlobal LifeSphere Regulatory

It is used by Merck, Teva, and several other multinational companies; the platform is recognized for its global applicability.

ArisGlobal's LifeSphere Regulatory platform incorporates AI-powered features throughout the entire regulatory lifecycle, from planning and writing to publishing and post-approval upkeep. The cognitive search engine of the platform swiftly finds pertinent regulatory information, speeding up document creation and minimizing the time spent sifting through archives. Tools for authoring, aided by AI, assist in creating or enhancing regulatory text, maintaining uniformity across modules and submissions. LifeSphere additionally offers automated workflow routing and updates on regulatory intelligence,

allowing teams to remain in sync with changing global regulations. Numerous global pharmaceutical firms depend on LifeSphere to effectively handle substantial submissions and ensure worldwide regulatory compliance. [58]

5.6 Microsoft Azure OpenAI-Integrated Workflows (Custom In-House Systems)

It is used by organizations such as Pfizer, Moderna, and GSK through custom implementations, the solution supports a wide range of industry needs.

Numerous major pharmaceutical firms are starting to create tailored AI solutions by combining Microsoft Azure's secure platform with OpenAI or other large language models (LLMs). These exclusive systems are designed specifically for generating regulatory documents, extracting data, and automating summarization. AI can extract information from study reports, clinical summaries, labeling documents, and validation datasets to create initial drafts of Module 2 sections, such as the clinical overview and nonclinical written summaries. These private LLM models conduct internal consistency assessments, standardize terminology across documents, and facilitate internal review processes. Due to functioning in secure, validated settings, they adhere to the stringent confidentiality standards of regulatory operations.

5.7 Docugami / Semantic AI Authoring Tools

Docugami and comparable semantic AI document-engineering platforms are gaining traction among smaller pharmaceutical and biotech firms looking for affordable automation for regulatory paperwork. These tools decompose unstructured documents into structured, machine-readable parts, facilitating the quick compilation of regulatory sections like clinical summaries, risk management plans, or quality narratives. AI models can recognize pertinent content, emphasize contradictions, and suggest uniform language in accordance with worldwide regulatory standards. These platforms assist in preserving version control and document consistency across various submissions, decreasing human mistakes and speeding up the creation of eCTD-compliant sections. [60]

6 Comparative Role of AI in NDA and ANDA Submissions [10][44]

Aspect	NDA Submissions	ANDA Submissions
Regulatory Focus	Demonstration of safety, efficacy, and quality	Demonstration of bioequivalence and sameness
Document Volume	Extremely high (CSRs, integrated summaries)	Moderate but repetitive across regions
Key AI Applications	CSR summarization, benefit–risk analysis, Module 2 drafting	Labeling sameness checks, BE data validation, lifecycle updates
Compliance Risk	Scientific inconsistency and interpretation	Technical rejections (RTF), formatting and lifecycle errors
AI Value Addition	Accelerates authoring and scientific coherence	Reduces manual errors and speeds high-volume submissions

7 CONCLUSION

Artificial Intelligence is fundamentally transforming the regulatory documentation landscape by providing answers to the enduring issues of complexity, expense, and compliance risk linked to eCTD, NDA, and ANDA submissions. The incorporation of AI tools for content creation, semantic verification, and predictive quality control has become not just a benefit but an essential requirement for operational excellence. As international health organizations progress towards the data-focused eCTD v4.0 standard,

AI-powered platforms will serve as the essential link uniting intricate scientific data with efficient, clear, and high-Caliber regulatory submissions. Successful adoption, nonetheless, depends on addressing compliance risks and effectively combining human expertise with technological proficiency.

8 REFERENCES

1. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). M4: Common Technical Document for the Registration of Pharmaceuticals for Human Use. Organisation of CTD. EMA; [cited 2025 Nov 23].https://www.ema.europa.eu/en/ich-m-4-common-technical-document-registration-pharmaceuticals-human-use-organisation-ctd-scientific-guideline
2. U.S. Food and Drug Administration. New Drug Application (NDA). Silver Spring (MD): FDA; [cited 2025 Nov 23].https://www.fda.gov/drugs/types-applications/new-drug-application-nda
3. Van Norman GA. Drugs, devices, and the FDA: Part 1 — "an overview of approval processes for drugs". JACC: Basic to Translational Science. 2016;1(3):170–179.
4. U.S. Food and Drug Administration. Electronic Common Technical Document (eCTD). Silver Spring (MD): FDA; [cited 2025 Nov 23]. https://www.fda.gov/drugs/electronic-regulatory-submission-and-review/electronic-common-technical-document-ectd
5. Saraswat R, Raikwar A, Panda S. Streamlining Regulatory Documentation: "Exploring the Common Technical Document (CTD) and Electronic Submission, with Emphasis on M Series According to ICH Guidelines". *Asian J Pharm Clin Res*. 2024;17(10): 52179.
6. Shivali S, et al. Cumbersome Lifecycle Tracking in eCTD: "The Resource-Intensive Nature of Replacing, Deleting, or Appending Documents Across Sequences". *Int J Drug Regulatory Affairs*. 2025;13(3):77–84.
7. PleasePublish.com. How Regulatory Publishing Automation Reduces Submission Timelines by 50%. [cited 2025 Nov 23]. https://www.pleasepublish.com/blog/how-regulatory-publishing-automation-reduces-submission-timelines/
8. Chandrasekaran K, Pramod Kumar TM, Balamuralidhara V. "The Regulatory Affairs Automation tools used in the Pharmaceutical Industry: An overview". *Int J Drug Regulatory Affairs*. 2024;12(1):36–39.
9. Boopathi KM, Raja N. "Artificial Intelligence and Machine Learning: Enhancing the Future of Regulatory Affairs". *Int J Drug Regulatory Affairs*. 2024;12(4).
10. Muppalla A, Maddi BD, Maddi NV. "Artificial Intelligence in Regulatory Compliance: Transforming Pharmaceutical and Healthcare Documentation". *Int J Drug Regulatory Affairs*. 2025;13(2):73–80.
11. DDReg Pharma. AI-Powered Regulatory Submissions: A New Era for IND, NDA, & BLA Documentation. DDReg Pharma Blog. 2025 [cited 2025 Nov 23]. https://resource.ddregpharma.com/blogs/ai-powered-regulatory-submissions-a-new-era-for-ind-nda-bla-documentation
12. Innovative Approaches in Regulatory Affairs: Leveraging Artificial Intelligence and Machine Learning for Efficient Compliance and Decision-Making. *Regul Aff Rev*. 2023. https://pubmed.ncbi.nlm.nih.gov/39776314/
13. Freyr Digital. How AI and NLP Are Transforming Regulatory Affairs Publishing. Freyr Digital; 2024.https://www.freyrdigital.com/what-is-articles/what-is-regulatory-affairs-publishing-and-how-is-ai-changing-it
14. Certara. CoAuthor™: Life Science GenAI Software for Medical Writing. Certara; [cited 2025 Nov 23]. https://www.certara.com/coauthor/
15. PPD. Harnessing Generative AI for Clinical Trial Documentation White Paper. PPD; [cited 2025 Nov 23]. https://www.ppd.com/our-solutions/clinical/functional-service-providers/medical-writing/harnessing-generative-ai-for-clinical-trial-documentation-white-paper/
16. IntuitionLabs.ai. GenAI Proof of Concept in Pharma: "Accelerating Drug Discovery and Development". IntuitionLabs.ai; 2025.
17. Narrativa. Generative AI for Life Sciences: Accelerate Regulatory Document Creation and Submission. Narrativa; [cited 2025 Nov 23]. https://www.narrativa.com/natural-language-generation-for-life-sciences/

18. TrialAssure / MMS. TrialAssure Announces AI Generative Text Partnership for Medical Writing. TrialAssure / MMS; 2023.
19. NuMantra. AI-Powered Compliance Validation: How to Build a Zero-Error eCTD Workflow. *NuMantraTech*. 2025 [cited 2025 Nov 23].https://numantratech.com/ai-powered-compliance-validation-how-to-build-a-zero-error-ectd-workflow
20. IntuitionLabs.ai. Using AI to Reduce Rework in Biotech Regulatory Submissions. IntuitionLabs; [cited 2025 Nov 23].https://intuitionlabs.ai/articles/ai-regulatory-submission-rework
21. "The synergy of artificial intelligence and machine learning in revolutionizing pharmaceutical regulatory affairs". *Translational Regulatory Science*. 2024;6(2).
22. AI-Powered Regulatory Submissions: "A New Era for IND, NDA, & BLA Documentation". DDReg pharma blog. 2025.
23. Anjaneyulu Muppalla, Beena Devi Maddi, Nagabhushanam V Maddi. "*Digitizing Regulatory Affairs with NLP"*. In: Int J Drug Regulatory Affairs. 2025;13(2):73-80.
24. Chandrasekaran K, Pramod Kumar TM, Balamuralidhara V. "Artificial Intelligence in Pharmaceutical Regulatory Affairs: An Introduction". *Asian J Biol Life Sci*. 2025;14(2):1–5.
25. Freyr Digital. Predictive Compliance in Pharma: How AI Forecasts Regulatory Risks. Freyr Digital; [cited 2025 Nov 23]. https://www.freyrsolutions.com/blog/predictive-compliance-in-pharma-how-ai-forecasts-regulatory-risks
26. Freyr Digital. 5 Generative AI Use Cases Revolutionizing Pharma Regulatory Affairs. Freyr Digital; [cited 2025 Nov 23]. https://www.freyrdigital.com/blog/5-generative-ai-use-cases-revolutionizing-pharma-regulatory-affairs
27. TCS. Envisioning Smart Regulatory Intelligence in Pharma. TCS ADD white paper; [cited 2025 Nov 23]. https://www.tcs.com/what-we-do/products-platforms/tcs-add/white-paper/envisioning-smart-regulatory-intelligence-in-pharma
28. Sudesamithiran N. A Review on Next Generation eCTD – eCTD v4.0. *Int J Drug Regul Aff*. 2023;11(4):67–73.
29. Loebel K-H. eCTD v4.0: A Look at 2025 and Beyond. *DIA Global Forum*. 2025 May issue.
30. Docuvera. eCTD 4.0 Structured Content Readiness. Docuvera; [cited 2025 Nov 23]. https://docuvera.com/why-docuvera/ectd-40/
31. NumAntraTech. Navigating eCTD 4.0: Regulatory Guide for Brazil, India, and Canada – Automation & Analytics. NumAntraTech; [cited 2025 Nov 23]. https://numantratech.com/navigating-ectd-4-0-regulatory-guide-for-brazil-india-and-canada/
32. FDA. eCTD Submission Standards for eCTD v4.0 and Regional M1. U.S. Food & Drug Administration; [cited 2025 Nov 23]. https://www.fda.gov/drugs/electronic-regulatory-submission-and-review/ectd-submission-standards-ectd-v40-and-regional-m1
33. Therapeutic Goods Administration (TGA). eCTD v4.0 AU module 1 and regional information: Use of HL7 RPS Release 2 Normative. TGA; [cited 2025 Nov 23]. https://www.tga.gov.au/resources/resource/user-guide/ectd-v40-au-module-1-and-regional-information
34. United States Food & Drug Administration. *Electronic Common Technical Document (eCTD) v4.0 Implementation Status*. FDA; [cited 2025 Nov 23]. https://www.fda.gov/drugs/electronic-regulatory-submission-and-review/electronic-common-technical-document-ectd-v40
35. United States Food & Drug Administration. *eCTD Submission Standards for eCTD v4.0 and Regional M1*. FDA; [cited 2025 Nov 23]. https://www.fda.gov/drugs/electronic-regulatory-submission-and-review/ectd-submission-standards-ectd-v40-and-regional-m1
36. U.S. FDA. *eCTD v4.0 Implementation Update – CDER / CBER*. FDA; 2024.
37. Loebel KH. eCTD v4.0: A Look at 2025 and beyond. *DIA Global Forum*. May 2025.
38. EXTEDO. New Milestone: EMA successfully moved to Step 2 of the eCTD v4.0 pilot. EXTEDO blog; [cited 2025 Nov 23].https://www.extedo.com/blog/new-milestone-reached-ema-has-successfully-moved-to-step-2-of-the-ectd-v4-pilot
39. European Medicines Agency. Update on electronic submissions and eAF – presentation by Kristiina Puusaari. EMA; [cited 2025 Nov 23]. https://www.ema.europa.eu/en/documents/presentation/presentation-1a-update-electronic-submissions-dadi-k-hamilton-k-puusaar_en.pdf
40. European Medicines Agency. "*Guideline on Computerised Systems and Electronic Data in Clinical Trials"*. EMA; 2023.

41. U.S. Food and Drug Administration. "*21 CFR Part 11: Electronic Records; Electronic Signatures"*. FDA; updated 2023.
42. ISPE. "GAMP 5 Guide: A Risk-Based Approach to Compliant GxP Computerized Systems". International Society for Pharmaceutical Engineering; 2022.
43. European Medicines Agency. "Reflection Paper on the Use of Artificial Intelligence in the Medicinal Product Lifecycle". EMA; 2023.
44. U.S. Food and Drug Administration. "Using Artificial Intelligence & Machine Learning in the Development of Drug and Biological Products". FDA Discussion Paper; 2023.
45. Deloitte. "AI-Powered Regulatory Affairs: Modernizing Compliance at Scale". Deloitte Insights; 2024.
46. PwC. "The True Cost of AI Adoption in Life Sciences: Infrastructure, Skills, Integration". PwC Life Sciences Outlook; 2024.
47. IQVIA. "The Future of Regulatory Submissions: Automation, GenAI, and Intelligent Dossier Assembly". IQVIA Whitepaper; 2024.
48. Freyr Digital. "AI-Enabled Regulatory Publishing and Compliance Automation". Freyr Digital; 2024.
49. European Medicines Agency. "*Reflection Paper on the Use of Artificial Intelligence in the Medicinal Product Lifecycle"*. EMA; 2023.
50. Mehrabi N, Morstatter F, Saxena N, et al. "A survey on bias and fairness in machine learning". *ACM Comput Surv*. 2021;54(6):1–35.
51. European Medicines Agency. "*Guideline on Computerised Systems and Electronic Data in Clinical Trials"*. EMA; 2023.
52. Fuentes R, Schofield S, Zahariev L. "The Role of Artificial Intelligence in Regulatory Affairs". *Regulatory Rapporteur*. 2025 Jan 10.
53. Docuvera. AI in Regulatory Affairs: Cutting Through the Hype. Docuvera blog; [cited 2025 Nov 23]. https://docuvera.com/blog/ai-in-regulatory-affairs/Docuvera
54. Bimal Kumar, Roussinov D. "NLP-based Regulatory Compliance — Using GPT-4.0 to Decode Regulatory Documents". 2024 Dec 29.
55. Kim J, Min M. From RAG to QA-RAG: "Integrating Generative AI for Pharmaceutical Regulatory Compliance". 2024 Jan 26.
56. Veeva Systems. *Veeva Vault RIM Driving Greater Speed and Compliance for More Than 350 Life Sciences Organizations.* PR Newswire; 2022 Oct 4.
57. IQVIA. *IQVIA Quality Management and Regulatory Suite Fact Sheet.* IQVIA; 2025 Apr 29.
58. ArisGlobal. *Regulatory | ArisGlobal LifeSphere Regulatory Platform.* ArisGlobal; 2026.
59. Freyr Digital. *Freyr SUBMIT PRO: Be Proactive. Be Productive. Be a Pro in Submissions.* FreyAFusion.com.
60. Docugami. *The Agentic System of Action for Business Users.* Docugami.com.